Clinical Trial Update: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

A Phase I study evaluating CUDC-427 for safety, tolerability and pharmacokinetics in patients with advanced and refractory solid tumors or lymphoma has been ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• CUDC-427

Snippet

Sponsor: Curis, Inc. | Conditions: Lymphoma | Phase 1 | Status: TERMINATED